Sydney Brenner, a professor at the Salk Institute for Biological Studies in La Jolla, Calif., shares this year’s Nobel Prize in medicine with H. Robert Horvitz and John E. Sulston, all awarded for their discoveries concerning genetic regulation of organ development and programmed cell death.
The laureates “have identified key genes regulating organ development and programmed cell death in worms and have shown that corresponding genes exist in higher species, including man,” said the Nobel committee in announcing the award last week in Sweden.
Brenner, whose pioneering work on Caenorhabditis elegans (C. elegans) established it as a novel experimental model organism, is director and principal scientific advisor for Lynx Therapeutics of Hayward, Calif., a company that engages in the discovery of gene expression patterns.
Jeffrey White leaves Agilent Technologies and joins NaPro BioTherapeutics of Boulder, Colo., as president of its newly-created genomics division, the company announced last week. White was the vice president and general manager of biochemistries and services for Agilent Technologies life sciences and chemical analysis group.
Prior to that, White was general manager of the chemistries and supplies division for the company, which split off from Hewlett-Packard three years ago. White worked in management and marketing for 15 years for Hewlett.
NaPro BioTherapeutics is a pharmaceutical company that seeks to develop or license novel pharmaceutical products.